Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma
Clinical Journal of Gastroenterology · 2024
DOI: 10.1007/s12328-024-02031-9 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Journal of Gastroenterology, 2024. Verfasst von Teppei Matsui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 6-11-…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Bevacizumab, Liver Neoplasms, Esophageal and Gastric Varices. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Bleeding-related adverse events may occur due to anti-vascular endothelial growth factors. Here, we report two cases of variceal rupture during atezolizumab plus bevacizumab (ATZ/BV) treatment for unresectable hepatocellular carcinoma (u-HCC).Case 1 involved a man in his 60 s with alcoholic liver cirrhosis (LC) and u-HCC. Seventy-four days after ATZ/BV administration, the patient was admitted for hematemesis. Upper esophagogastroduodenoscopy (EGD) revealed worsening of the esophageal varices (EVs) to F2 grade with active bleeding. Endoscopic variceal ligation successfully achieved hemostasis.Case 2 involved a man in his 70 s with alcoholic LC and u-HCC. The patient was admitted with hematemesis 114 days after ATZ/BV administration. During EGD, the EVs deteriorated to F3 grade, although hemostasis had already been achieved. The evaluation was discontinued during the observation stage because of the worsening hepatic reserve.Neither patient had EVs warranting prophylactic treatment before ATZ/BV administration, showed a partial tumor response, or had portal vein tumor thrombus. Both patients demonstrated increased total diameters of the collateral veins and splenic volume compared to those before treatment. These findings suggest that ATZ/BV treatment may increase portal pressure. In conclusion, the administration of ATZ/BV to patients with LC and u-HCC necessitates careful management of EVs aggravation and rupture.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 6-11-1, Omorinishi, Ota-ku, Tokyo, 143-8541, Japan. teppei.matsui@med.toho-…
- Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 6-11-1, Omorinishi, Ota-ku, Tokyo, 143-8541, Japan.
Zitieren
APA
Matsui, T., Nagai, H., Mukozu, T., Wakui, N., Matsuda, T., & Igarashi, Y. (2024). Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-024-02031-9
Vancouver
Matsui T, Nagai H, Mukozu T, Wakui N, Matsuda T, Igarashi Y. Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology. 2024. doi:10.1007/s12328-024-02031-9
BibTeX
@article{Matsui2024,
author = {Matsui, Teppei and Nagai, Hidenari and Mukozu, Takanori and Wakui, Noritaka and Matsuda, Takahisa and Igarashi, Yoshinori},
title = {Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma},
journal = {Clinical Journal of Gastroenterology},
year = {2024},
doi = {10.1007/s12328-024-02031-9}
}
EUVIMED